Vaxart, Inc. (NASDAQ:VXRT) CFO Acquires $16,100.00 in Stock

Vaxart, Inc. (NASDAQ:VXRTGet Rating) CFO Fuad Ahmad acquired 5,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was acquired at an average price of $3.22 per share, for a total transaction of $16,100.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $16,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of VXRT stock traded up $0.26 during trading hours on Thursday, hitting $3.69. The stock had a trading volume of 2,771,725 shares, compared to its average volume of 2,662,238. Vaxart, Inc. has a one year low of $2.49 and a one year high of $10.33. The stock’s 50-day moving average price is $3.54 and its two-hundred day moving average price is $4.74. The stock has a market capitalization of $466.44 million, a price-to-earnings ratio of -5.77 and a beta of 0.67.

Vaxart (NASDAQ:VXRTGet Rating) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Vaxart had a negative return on equity of 41.95% and a negative net margin of 16,892.57%. The firm had revenue of $0.09 million during the quarter. As a group, analysts forecast that Vaxart, Inc. will post -0.75 EPS for the current year.

Hedge funds have recently modified their holdings of the company. Citigroup Inc. increased its holdings in shares of Vaxart by 179.8% in the fourth quarter. Citigroup Inc. now owns 660,978 shares of the biotechnology company’s stock worth $4,144,000 after purchasing an additional 424,746 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Vaxart by 4.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 249,839 shares of the biotechnology company’s stock worth $1,566,000 after acquiring an additional 10,233 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Vaxart by 281.8% during the third quarter. Goldman Sachs Group Inc. now owns 154,835 shares of the biotechnology company’s stock worth $1,231,000 after acquiring an additional 114,282 shares during the last quarter. AE Wealth Management LLC increased its stake in Vaxart by 45.6% during the fourth quarter. AE Wealth Management LLC now owns 16,203 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 5,078 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Vaxart by 2.0% during the fourth quarter. Northern Trust Corp now owns 1,232,150 shares of the biotechnology company’s stock worth $7,725,000 after acquiring an additional 24,250 shares during the last quarter. 45.91% of the stock is currently owned by hedge funds and other institutional investors.

Separately, B. Riley lowered their price objective on Vaxart from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Thursday, May 19th.

Vaxart Company Profile (Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Featured Stories

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.